Affordable Access

Access to the full text

Outcome Assessments in Rheumatoid Arthritis

Authors
  • Gilek-Seibert, Katarzyna1
  • Prescott, Kara1
  • Kazi, Salahuddin1
  • 1 UT Southwestern Medical Center, Division of Rheumatic Diseases, 5323 Harry Hines Blvd, Dallas, TX, 75390-8884, USA , Dallas (United States)
Type
Published Article
Journal
Current Rheumatology Reports
Publisher
Springer-Verlag
Publication Date
Sep 27, 2013
Volume
15
Issue
11
Identifiers
DOI: 10.1007/s11926-013-0370-y
Source
Springer Nature
Keywords
License
Yellow

Abstract

Increasing evidence suggests low disease activity or remission is achievable in rheumatoid arthritis (RA). Using a treat to target strategy (T2T) has been shown to achieve these targets of remission or low disease activity in RA. In order to successfully treat to target, rheumatologists need reliable measures of disease activity to switch and/or escalate therapy to achieve or maintain therapeutic targets. Multiple disease-activity measures have been developed for both research and clinical practice. For clinical practice, the American College of Rheumatology (ACR) has recommended the PAS, PAS II, RAPID 3, CDAI, DAS 28, and SDAI for measuring disease activity in rheumatoid arthritis. Each of these measures has strengths and limitations, but they all accurately reflect disease activity, discriminate well between disease states, and are feasible to perform in the clinical setting. Implementation in the clinical setting can be optimized through leveraging technology and systems redesign. Tools such as web-based and smartphone applications have been developed to increase the ease with which these measures can be deployed. Disease-activity measurement in rheumatoid arthritis is included in the rheumatoid arthritis quality measures group in the Centers for Medicare and Medicaid Services’ incentive-based Physician Quality Reporting System.

Report this publication

Statistics

Seen <100 times